{
  "docId": "019de074-7472-72bc-8651-e49cc0d0319c",
  "docSlug": "c2a880ad0c526527fe8aa49c40270224",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 28,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes both longitudinal efficacy data (line chart) and pharmacokinetic data (bar charts) comparing plasma vs liver concentrations.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/23",
  "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c",
  "deckJsonHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c.json",
  "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.25,
        "x": 0.7,
        "y": 0.45
      },
      "kind": "chart",
      "text": "Fraction Unbound Concentrations (C24h) [AB-161]free: liver",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "491d9343-2906-49b4-96a7-d5a1c421b5eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.45,
        "y": 0.45
      },
      "kind": "chart",
      "text": "Fraction Unbound Concentrations (C24h) [AB-161]free: plasma",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e727b581-7d04-4e6f-98af-20c2626610cf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.07,
        "y": 0.45
      },
      "kind": "chart",
      "text": "AAV-HBV mouse AB-161 QD for 14 days",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7a89dea1-c0b6-4863-9587-0fcb932361e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.07,
        "y": 0.18
      },
      "kind": "list",
      "text": "AB-161 effective as a once-daily dose in AAV-HBV mouse model (0.3, 1, 10, 30 mg/kg QD)\nDose-dependent reduction of HBsAg, also observed with BID dosing (0.3 and 1 mg/kg BID)\nHBsAg reduction achieved when fraction unbound C24h > EC90 in liver",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2499f21-9e7a-4b9e-93ac-b53b08c63f63",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.15,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Data presented at Discovery on Target Conference, October 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7bedff3d-5c9f-423a-8692-f25e971fe901",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "Compound concentration in liver drives efficacy",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "344933c6-6ad9-4e27-ab5f-15b7a35662f0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "AB-161 Reduces HBsAg in AAV-HBV Mouse Model",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16fb63c7-a07e-41cd-8819-cf55f53df068",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "e07505b4-fdf0-416e-9ef3-2a49cb232aab",
      "evidence": "chart/bar-vertical: Fraction Unbound Concentrations (C24h) [AB-161]free: plasma",
      "confidence": 0.7
    },
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "0b4fdba6-cf9b-4266-9e83-00de851f4657",
      "evidence": "chart/bar-vertical: Fraction Unbound Concentrations (C24h) [AB-161]free: liver",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 8,
      "beatId": "8e825e5a-e303-4698-98f8-f2a022a4a5c6",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-729, AB-101, and AB-161, as a potential solution (p8-28).",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    },
    {
      "to": 28,
      "from": 17,
      "beatId": "f38a537d-5a41-47d5-be5b-904ed8c0f42a",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "The document outlines the next steps for AB-729 and other pipeline programs (p17-28).",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}